HAEM5:Paediatric nodal marginal zone lymphoma: Difference between revisions
| [checked revision] | [checked revision] |
Bailey.Glen (talk | contribs) No edit summary |
Bailey.Glen (talk | contribs) No edit summary |
||
| (4 intermediate revisions by the same user not shown) | |||
| Line 4: | Line 4: | ||
{{Under Construction}} | {{Under Construction}} | ||
<blockquote class= | <blockquote class="blockedit">{{Box-round|title=Content Update To WHO 5th Edition Classification Is In Process; Content Below is Based on WHO 4th Edition Classification|This page was converted to the new template on 2023-12-07. The original page can be found at [[HAEM4:Paediatric Nodal Marginal Zone Lymphoma]]. | ||
}}</blockquote> | }}</blockquote> | ||
| Line 11: | Line 11: | ||
==Primary Author(s)*== | ==Primary Author(s)*== | ||
* Kathleen M. Schieffer, PhD | *Kathleen M. Schieffer, PhD | ||
* Ruthann Pfau, PhD | *Ruthann Pfau, PhD | ||
==WHO Classification of Disease== | ==WHO Classification of Disease== | ||
| Line 38: | Line 35: | ||
|} | |} | ||
== | ==Related Terminology== | ||
{| class="wikitable" | {| class="wikitable" | ||
|+ | |+ | ||
|Acceptable | |Acceptable | ||
| | |N/A | ||
|- | |- | ||
|Not Recommended | |Not Recommended | ||
| | |Monocytoid B-cell lymphoma; parafollicular B-cell lymphoma | ||
|} | |} | ||
| Line 209: | Line 109: | ||
|} | |} | ||
<blockquote class= | <blockquote class="blockedit">{{Box-round|title=v4:Chromosomal Rearrangements (Gene Fusions)|The content below was from the old template. Please incorporate above.}}</blockquote> | ||
* No chromosomal rearrangements or gene fusions associated with pNMZL<ref name=":0" /> | *No chromosomal rearrangements or gene fusions associated with pNMZL<ref name=":0">{{Cite journal|last=Ozawa|first=Michael G.|last2=Bhaduri|first2=Aparna|last3=Chisholm|first3=Karen M.|last4=Baker|first4=Steven A.|last5=Ma|first5=Lisa|last6=Zehnder|first6=James L.|last7=Luna-Fineman|first7=Sandra|last8=Link|first8=Michael P.|last9=Merker|first9=Jason D.|date=10 2016|title=A study of the mutational landscape of pediatric-type follicular lymphoma and pediatric nodal marginal zone lymphoma|url=https://pubmed.ncbi.nlm.nih.gov/27338637|journal=Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc|volume=29|issue=10|pages=1212–1220|doi=10.1038/modpathol.2016.102|issn=1530-0285|pmc=5047957|pmid=27338637}}</ref> | ||
* Clonal rearrangements of immunoglobulin (Ig) region detected in most cases<ref name=":3" /><ref name=":9" /> | *Clonal rearrangements of immunoglobulin (Ig) region detected in most cases<ref name=":3">{{Cite journal|last=Koo|first=Matthew|last2=Ohgami|first2=Robert S.|date=2017-05|title=Pediatric-type Follicular Lymphoma and Pediatric Nodal Marginal Zone Lymphoma: Recent Clinical, Morphologic, Immunophenotypic, and Genetic Insights|url=https://pubmed.ncbi.nlm.nih.gov/28277421|journal=Advances in Anatomic Pathology|volume=24|issue=3|pages=128–135|doi=10.1097/PAP.0000000000000144|issn=1533-4031|pmid=28277421}}</ref><ref name=":9">{{Cite journal|displayauthors=1|last=Rizzo|first=Kathryn|date=|title=Marginal zone lymphomas in children and the young adult population; characterization of genetic aberrations by FISH and RT-PCR|url=|journal=Mol Pathol|volume=23|pages=866-873|doi=10.1038/modpathol.2010.63|pmc=PMC6329460|pmid=20305621|via=}}</ref> | ||
<blockquote class="blockedit"> | <blockquote class="blockedit"> | ||
| Line 220: | Line 120: | ||
<blockquote class= | <blockquote class="blockedit">{{Box-round|title=v4:Clinical Significance (Diagnosis, Prognosis and Therapeutic Implications).|Please incorporate this section into the relevant tables found in: | ||
* Chromosomal Rearrangements (Gene Fusions) | * Chromosomal Rearrangements (Gene Fusions) | ||
* Individual Region Genomic Gain/Loss/LOH | * Individual Region Genomic Gain/Loss/LOH | ||
| Line 226: | Line 126: | ||
* Gene Mutations (SNV/INDEL)}}</blockquote> | * Gene Mutations (SNV/INDEL)}}</blockquote> | ||
* No genomic findings currently assist in diagnosis, prognostication, or therapeutic decisions | *No genomic findings currently assist in diagnosis, prognostication, or therapeutic decisions | ||
<blockquote class="blockedit"> | <blockquote class="blockedit"> | ||
| Line 238: | Line 138: | ||
{| class="wikitable sortable" | {| class="wikitable sortable" | ||
|- | |- | ||
!Chr #!! | !Chr #!!Gain, Loss, Amp, LOH!!Minimal Region Cytoband and/or Genomic Coordinates [Genome Build; Size]!!Relevant Gene(s) | ||
! | !Diagnostic, Prognostic, and Therapeutic Significance - D, P, T | ||
! | !Established Clinical Significance Per Guidelines - Yes or No (Source) | ||
! | !Clinical Relevance Details/Other Notes | ||
|- | |- | ||
|<span class="blue-text">EXAMPLE:</span> | |<span class="blue-text">EXAMPLE:</span> | ||
| Line 288: | Line 188: | ||
|} | |} | ||
<blockquote class= | <blockquote class="blockedit">{{Box-round|title=v4:Genomic Gain/Loss/LOH|The content below was from the old template. Please incorporate above.}}</blockquote> | ||
* Trisomy 3 and 18 are infrequently described chromosomal aberrations reported in pNMZL<ref name=":9" /> | *Trisomy 3 and 18 are infrequently described chromosomal aberrations reported in pNMZL<ref name=":9" /> | ||
** These chromosome gains have also been described in adult-type NMZL<ref name=":2" /><ref>{{Cite journal|last=Rinaldi|first=Andrea|last2=Mian|first2=Michael|last3=Chigrinova|first3=Ekaterina|last4=Arcaini|first4=Luca|last5=Bhagat|first5=Govind|last6=Novak|first6=Urban|last7=Rancoita|first7=Paola M. V.|last8=De Campos|first8=Cassio P.|last9=Forconi|first9=Francesco|date=2011-02-03|title=Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome|url=https://pubmed.ncbi.nlm.nih.gov/21115979|journal=Blood|volume=117|issue=5|pages=1595–1604|doi=10.1182/blood-2010-01-264275|issn=1528-0020|pmid=21115979}}</ref><ref>{{Cite journal|last=Dierlamm|first=J.|last2=Pittaluga|first2=S.|last3=Wlodarska|first3=I.|last4=Stul|first4=M.|last5=Thomas|first5=J.|last6=Boogaerts|first6=M.|last7=Michaux|first7=L.|last8=Driessen|first8=A.|last9=Mecucci|first9=C.|date=1996-01-01|title=Marginal zone B-cell lymphomas of different sites share similar cytogenetic and morphologic features|url=https://pubmed.ncbi.nlm.nih.gov/8547655|journal=Blood|volume=87|issue=1|pages=299–307|issn=0006-4971|pmid=8547655}}</ref> | **These chromosome gains have also been described in adult-type NMZL<ref name=":2">Swerdlow SH, Campo E, Harris NL et al (eds) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press, Lyon, pp 263-264</ref><ref>{{Cite journal|last=Rinaldi|first=Andrea|last2=Mian|first2=Michael|last3=Chigrinova|first3=Ekaterina|last4=Arcaini|first4=Luca|last5=Bhagat|first5=Govind|last6=Novak|first6=Urban|last7=Rancoita|first7=Paola M. V.|last8=De Campos|first8=Cassio P.|last9=Forconi|first9=Francesco|date=2011-02-03|title=Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome|url=https://pubmed.ncbi.nlm.nih.gov/21115979|journal=Blood|volume=117|issue=5|pages=1595–1604|doi=10.1182/blood-2010-01-264275|issn=1528-0020|pmid=21115979}}</ref><ref>{{Cite journal|last=Dierlamm|first=J.|last2=Pittaluga|first2=S.|last3=Wlodarska|first3=I.|last4=Stul|first4=M.|last5=Thomas|first5=J.|last6=Boogaerts|first6=M.|last7=Michaux|first7=L.|last8=Driessen|first8=A.|last9=Mecucci|first9=C.|date=1996-01-01|title=Marginal zone B-cell lymphomas of different sites share similar cytogenetic and morphologic features|url=https://pubmed.ncbi.nlm.nih.gov/8547655|journal=Blood|volume=87|issue=1|pages=299–307|issn=0006-4971|pmid=8547655}}</ref> | ||
{| class="wikitable sortable" | {| class="wikitable sortable" | ||
| Line 311: | Line 211: | ||
|Whole chromosome | |Whole chromosome | ||
|0-5% | |0-5% | ||
|<ref name=":10" /> | |<ref name=":10">{{Cite journal|last=Elenitoba-Johnson|first=K. S.|last2=Kumar|first2=S.|last3=Lim|first3=M. S.|last4=Kingma|first4=D. W.|last5=Raffeld|first5=M.|last6=Jaffe|first6=E. S.|date=1997-01|title=Marginal zone B-cell lymphoma with monocytoid B-cell lymphocytes in pediatric patients without immunodeficiency. A report of two cases|url=https://pubmed.ncbi.nlm.nih.gov/8980374|journal=American Journal of Clinical Pathology|volume=107|issue=1|pages=92–98|doi=10.1093/ajcp/107.1.92|issn=0002-9173|pmid=8980374}}</ref> | ||
|} | |} | ||
| Line 326: | Line 226: | ||
!Chromosomal Pattern | !Chromosomal Pattern | ||
!Molecular Pathogenesis | !Molecular Pathogenesis | ||
! | !Prevalence - | ||
Common >20%, Recurrent 5-20% or Rare <5% (Disease) | |||
! | !Diagnostic, Prognostic, and Therapeutic Significance - D, P, T | ||
! | !Established Clinical Significance Per Guidelines - Yes or No (Source) | ||
! | !Clinical Relevance Details/Other Notes | ||
|- | |- | ||
|<span class="blue-text">EXAMPLE:</span> | |<span class="blue-text">EXAMPLE:</span> | ||
| Line 356: | Line 256: | ||
|} | |} | ||
<blockquote class= | <blockquote class="blockedit">{{Box-round|title=v4:Characteristic Chromosomal Aberrations / Patterns|The content below was from the old template. Please incorporate above.}}</blockquote> | ||
* No characteristic chromosomal aberrations or patterns reported | *No characteristic chromosomal aberrations or patterns reported | ||
<blockquote class="blockedit"> | <blockquote class="blockedit"> | ||
| Line 370: | Line 270: | ||
{| class="wikitable sortable" | {| class="wikitable sortable" | ||
|- | |- | ||
!Gene!! | !Gene!!Genetic Alteration!!Tumor Suppressor Gene, Oncogene, Other!!Prevalence - | ||
Common >20%, Recurrent 5-20% or Rare <5% (Disease) | |||
! | !Diagnostic, Prognostic, and Therapeutic Significance - D, P, T | ||
! | !Established Clinical Significance Per Guidelines - Yes or No (Source) | ||
! | !Clinical Relevance Details/Other Notes | ||
|- | |- | ||
|<span class="blue-text">EXAMPLE:</span>''EGFR'' | |<span class="blue-text">EXAMPLE:</span>''EGFR'' | ||
| Line 412: | Line 312: | ||
|}Note: A more extensive list of mutations can be found in [https://www.cbioportal.org/ <u>cBioportal</u>], [https://cancer.sanger.ac.uk/cosmic <u>COSMIC</u>], and/or other databases. When applicable, gene-specific pages within the CCGA site directly link to pertinent external content. | |}Note: A more extensive list of mutations can be found in [https://www.cbioportal.org/ <u>cBioportal</u>], [https://cancer.sanger.ac.uk/cosmic <u>COSMIC</u>], and/or other databases. When applicable, gene-specific pages within the CCGA site directly link to pertinent external content. | ||
<blockquote class= | <blockquote class="blockedit">{{Box-round|title=v4:Gene Mutations (SNV/INDEL)|The content below was from the old template. Please incorporate above.}}</blockquote> | ||
* Genes reported to be altered in adult-type NMZL, including ''MLL2 (KMT2D), PTPRD, NOTCH2, KLF2,'' and ''BRAF'',<ref>{{Cite journal|last=Spina|first=Valeria|last2=Khiabanian|first2=Hossein|last3=Messina|first3=Monica|last4=Monti|first4=Sara|last5=Cascione|first5=Luciano|last6=Bruscaggin|first6=Alessio|last7=Spaccarotella|first7=Elisa|last8=Holmes|first8=Antony B.|last9=Arcaini|first9=Luca|date=09 08, 2016|title=The genetics of nodal marginal zone lymphoma|url=https://pubmed.ncbi.nlm.nih.gov/27335277|journal=Blood|volume=128|issue=10|pages=1362–1373|doi=10.1182/blood-2016-02-696757|issn=1528-0020|pmc=5016706|pmid=27335277}}</ref><ref>{{Cite journal|last=Pillonel|first=V.|last2=Juskevicius|first2=D.|last3=Ng|first3=C. K. Y.|last4=Bodmer|first4=A.|last5=Zettl|first5=A.|last6=Jucker|first6=D.|last7=Dirnhofer|first7=S.|last8=Tzankov|first8=A.|date=11 2018|title=High-throughput sequencing of nodal marginal zone lymphomas identifies recurrent BRAF mutations|url=https://pubmed.ncbi.nlm.nih.gov/29556019|journal=Leukemia|volume=32|issue=11|pages=2412–2426|doi=10.1038/s41375-018-0082-4|issn=1476-5551|pmc=6224405|pmid=29556019}}</ref> have not been described in pNMZL<ref name=":0" /> | *Genes reported to be altered in adult-type NMZL, including ''MLL2 (KMT2D), PTPRD, NOTCH2, KLF2,'' and ''BRAF'',<ref>{{Cite journal|last=Spina|first=Valeria|last2=Khiabanian|first2=Hossein|last3=Messina|first3=Monica|last4=Monti|first4=Sara|last5=Cascione|first5=Luciano|last6=Bruscaggin|first6=Alessio|last7=Spaccarotella|first7=Elisa|last8=Holmes|first8=Antony B.|last9=Arcaini|first9=Luca|date=09 08, 2016|title=The genetics of nodal marginal zone lymphoma|url=https://pubmed.ncbi.nlm.nih.gov/27335277|journal=Blood|volume=128|issue=10|pages=1362–1373|doi=10.1182/blood-2016-02-696757|issn=1528-0020|pmc=5016706|pmid=27335277}}</ref><ref>{{Cite journal|last=Pillonel|first=V.|last2=Juskevicius|first2=D.|last3=Ng|first3=C. K. Y.|last4=Bodmer|first4=A.|last5=Zettl|first5=A.|last6=Jucker|first6=D.|last7=Dirnhofer|first7=S.|last8=Tzankov|first8=A.|date=11 2018|title=High-throughput sequencing of nodal marginal zone lymphomas identifies recurrent BRAF mutations|url=https://pubmed.ncbi.nlm.nih.gov/29556019|journal=Leukemia|volume=32|issue=11|pages=2412–2426|doi=10.1038/s41375-018-0082-4|issn=1476-5551|pmc=6224405|pmid=29556019}}</ref> have not been described in pNMZL<ref name=":0" /> | ||
* While no recurrent somatic variations have been identified in pNMZL, a somatic variant in ''AMOTL1'' (NM_130847, p.Ala891Thr) was reported in a single individual with pNMZL<ref name=":0" /> | *While no recurrent somatic variations have been identified in pNMZL, a somatic variant in ''AMOTL1'' (NM_130847, p.Ala891Thr) was reported in a single individual with pNMZL<ref name=":0" /> | ||
** Missense alterations in ''AMOTL1'' have been reported in adult splenic marginal zone lymphoma (p.Ala424Thr and p.Val361Ile)<ref>{{Cite journal|last=Parry|first=Marina|last2=Rose-Zerilli|first2=Matthew J. J.|last3=Gibson|first3=Jane|last4=Ennis|first4=Sarah|last5=Walewska|first5=Renata|last6=Forster|first6=Jade|last7=Parker|first7=Helen|last8=Davis|first8=Zadie|last9=Gardiner|first9=Anne|date=2013|title=Whole exome sequencing identifies novel recurrently mutated genes in patients with splenic marginal zone lymphoma|url=https://pubmed.ncbi.nlm.nih.gov/24349473|journal=PloS One|volume=8|issue=12|pages=e83244|doi=10.1371/journal.pone.0083244|issn=1932-6203|pmc=3862727|pmid=24349473}}</ref><ref>{{Cite journal|last=Rossi|first=Davide|last2=Trifonov|first2=Vladimir|last3=Fangazio|first3=Marco|last4=Bruscaggin|first4=Alessio|last5=Rasi|first5=Silvia|last6=Spina|first6=Valeria|last7=Monti|first7=Sara|last8=Vaisitti|first8=Tiziana|last9=Arruga|first9=Francesca|date=2012-08-27|title=The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development|url=https://pubmed.ncbi.nlm.nih.gov/22891273|journal=The Journal of Experimental Medicine|volume=209|issue=9|pages=1537–1551|doi=10.1084/jem.20120904|issn=1540-9538|pmc=3428941|pmid=22891273}}</ref> and other cancers ([https://cancer.sanger.ac.uk/cosmic/mutation/overview?id=122769838 COSMIC], [http://www.cbioportal.org/ cBioPortal], [https://pedcbioportal.kidsfirstdrc.org/ PedcBioPortal]) | **Missense alterations in ''AMOTL1'' have been reported in adult splenic marginal zone lymphoma (p.Ala424Thr and p.Val361Ile)<ref>{{Cite journal|last=Parry|first=Marina|last2=Rose-Zerilli|first2=Matthew J. J.|last3=Gibson|first3=Jane|last4=Ennis|first4=Sarah|last5=Walewska|first5=Renata|last6=Forster|first6=Jade|last7=Parker|first7=Helen|last8=Davis|first8=Zadie|last9=Gardiner|first9=Anne|date=2013|title=Whole exome sequencing identifies novel recurrently mutated genes in patients with splenic marginal zone lymphoma|url=https://pubmed.ncbi.nlm.nih.gov/24349473|journal=PloS One|volume=8|issue=12|pages=e83244|doi=10.1371/journal.pone.0083244|issn=1932-6203|pmc=3862727|pmid=24349473}}</ref><ref>{{Cite journal|last=Rossi|first=Davide|last2=Trifonov|first2=Vladimir|last3=Fangazio|first3=Marco|last4=Bruscaggin|first4=Alessio|last5=Rasi|first5=Silvia|last6=Spina|first6=Valeria|last7=Monti|first7=Sara|last8=Vaisitti|first8=Tiziana|last9=Arruga|first9=Francesca|date=2012-08-27|title=The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development|url=https://pubmed.ncbi.nlm.nih.gov/22891273|journal=The Journal of Experimental Medicine|volume=209|issue=9|pages=1537–1551|doi=10.1084/jem.20120904|issn=1540-9538|pmc=3428941|pmid=22891273}}</ref> and other cancers ([https://cancer.sanger.ac.uk/cosmic/mutation/overview?id=122769838 COSMIC], [http://www.cbioportal.org/ cBioPortal], [https://pedcbioportal.kidsfirstdrc.org/ PedcBioPortal]) | ||
{| class="wikitable sortable" | {| class="wikitable sortable" | ||
| Line 430: | Line 330: | ||
===Other Mutations=== | ===Other Mutations=== | ||
* Additional studies are needed to assess the spectrum of somatic variation in pNMZL. A single report evaluated the genetic landscape of pNMZL by whole exome sequencing (n=4) identified missense changes in the following genes: ''AMOTL1, SCAF1, SELPLG, FAM5B, KLHDC4, RAX, PEG3, CHPF, ACTRT3, NRCAM, CHMP1A, CISH, TTC17, NLE1<ref name=":0" />'' | *Additional studies are needed to assess the spectrum of somatic variation in pNMZL. A single report evaluated the genetic landscape of pNMZL by whole exome sequencing (n=4) identified missense changes in the following genes: ''AMOTL1, SCAF1, SELPLG, FAM5B, KLHDC4, RAX, PEG3, CHPF, ACTRT3, NRCAM, CHMP1A, CISH, TTC17, NLE1<ref name=":0" />'' | ||
<blockquote class="blockedit"> | <blockquote class="blockedit"> | ||
| Line 438: | Line 338: | ||
==Epigenomic Alterations== | ==Epigenomic Alterations== | ||
* None | *None | ||
==Genes and Main Pathways Involved== | ==Genes and Main Pathways Involved== | ||
| Line 465: | Line 365: | ||
|} | |} | ||
<blockquote class= | <blockquote class="blockedit">{{Box-round|title=v4:Genes and Main Pathways Involved|The content below was from the old template. Please incorporate above.}}</blockquote> | ||
* ''AMOTL1'' encodes angiomotin like-1 which associates with tight junctions and regulates the Hippo signaling pathway<ref>{{Cite journal|last=Yi|first=Chunling|last2=Troutman|first2=Scott|last3=Fera|first3=Daniela|last4=Stemmer-Rachamimov|first4=Anat|last5=Avila|first5=Jacqueline L.|last6=Christian|first6=Neepa|last7=Persson|first7=Nathalie Luna|last8=Shimono|first8=Akihiko|last9=Speicher|first9=David W.|date=2011-04-12|title=A tight junction-associated Merlin-angiomotin complex mediates Merlin's regulation of mitogenic signaling and tumor suppressive functions|url=https://pubmed.ncbi.nlm.nih.gov/21481793|journal=Cancer Cell|volume=19|issue=4|pages=527–540|doi=10.1016/j.ccr.2011.02.017|issn=1878-3686|pmc=3075552|pmid=21481793}}</ref><ref>{{Cite journal|last=Lv|first=Meng|last2=Shen|first2=Yanwei|last3=Yang|first3=Jiao|last4=Li|first4=Shuting|last5=Wang|first5=Biyuan|last6=Chen|first6=Zheling|last7=Li|first7=Pan|last8=Liu|first8=Peijun|last9=Yang|first9=Jin|date=2017|title=Angiomotin Family Members: Oncogenes or Tumor Suppressors?|url=https://pubmed.ncbi.nlm.nih.gov/28656002|journal=International Journal of Biological Sciences|volume=13|issue=6|pages=772–781|doi=10.7150/ijbs.19603|issn=1449-2288|pmc=5485632|pmid=28656002}}</ref> | *''AMOTL1'' encodes angiomotin like-1 which associates with tight junctions and regulates the Hippo signaling pathway<ref>{{Cite journal|last=Yi|first=Chunling|last2=Troutman|first2=Scott|last3=Fera|first3=Daniela|last4=Stemmer-Rachamimov|first4=Anat|last5=Avila|first5=Jacqueline L.|last6=Christian|first6=Neepa|last7=Persson|first7=Nathalie Luna|last8=Shimono|first8=Akihiko|last9=Speicher|first9=David W.|date=2011-04-12|title=A tight junction-associated Merlin-angiomotin complex mediates Merlin's regulation of mitogenic signaling and tumor suppressive functions|url=https://pubmed.ncbi.nlm.nih.gov/21481793|journal=Cancer Cell|volume=19|issue=4|pages=527–540|doi=10.1016/j.ccr.2011.02.017|issn=1878-3686|pmc=3075552|pmid=21481793}}</ref><ref>{{Cite journal|last=Lv|first=Meng|last2=Shen|first2=Yanwei|last3=Yang|first3=Jiao|last4=Li|first4=Shuting|last5=Wang|first5=Biyuan|last6=Chen|first6=Zheling|last7=Li|first7=Pan|last8=Liu|first8=Peijun|last9=Yang|first9=Jin|date=2017|title=Angiomotin Family Members: Oncogenes or Tumor Suppressors?|url=https://pubmed.ncbi.nlm.nih.gov/28656002|journal=International Journal of Biological Sciences|volume=13|issue=6|pages=772–781|doi=10.7150/ijbs.19603|issn=1449-2288|pmc=5485632|pmid=28656002}}</ref> | ||
<blockquote class="blockedit"> | <blockquote class="blockedit"> | ||
| Line 475: | Line 375: | ||
==Genetic Diagnostic Testing Methods== | ==Genetic Diagnostic Testing Methods== | ||
* Histopathology and immunophenotyping | *Histopathology and immunophenotyping | ||
* Molecular testing (i.e. clonality assessment) | *Molecular testing (i.e. clonality assessment) | ||
==Familial Forms== | ==Familial Forms== | ||
* Not described | *Not described | ||
==Additional Information== | ==Additional Information== | ||
* None | *None | ||
==Links== | ==Links== | ||
* [[HAEM5:Nodal marginal zone lymphoma]] | *[[HAEM5:Nodal marginal zone lymphoma]] | ||
* [[HAEM5:Paediatric-type follicular lymphoma]] | *[[HAEM5:Paediatric-type follicular lymphoma]] | ||
==References== | ==References== | ||
(use the "Cite" icon at the top of the page) <span style="color:#0070C0">(''Instructions: Add each reference into the text above by clicking where you want to insert the reference, selecting the “Cite” icon at the top of the wiki page, and using the “Automatic” tab option to search by PMID to select the reference to insert. If a PMID is not available, such as for a book, please use the “Cite” icon, select “Manual” and then “Basic Form”, and include the entire reference. To insert the same reference again later in the page, select the “Cite” icon and “Re-use” to find the reference; DO NOT insert the same reference twice using the “Automatic” tab as it will be treated as two separate references. The reference list in this section will be automatically generated and sorted''</span><span style="color:#0070C0">''.''</span><span style="color:#0070C0">)</span> <references /> | (use the "Cite" icon at the top of the page) <span style="color:#0070C0">(''Instructions: Add each reference into the text above by clicking where you want to insert the reference, selecting the “Cite” icon at the top of the wiki page, and using the “Automatic” tab option to search by PMID to select the reference to insert. If a PMID is not available, such as for a book, please use the “Cite” icon, select “Manual” and then “Basic Form”, and include the entire reference. To insert the same reference again later in the page, select the “Cite” icon and “Re-use” to find the reference; DO NOT insert the same reference twice using the “Automatic” tab as it will be treated as two separate references. The reference list in this section will be automatically generated and sorted''</span><span style="color:#0070C0">''.''</span><span style="color:#0070C0">)</span> <references /> | ||
<br /> | |||
==Notes== | ==Notes== | ||
| Line 503: | Line 403: | ||
<nowiki>*</nowiki>''Citation of this Page'': “Paediatric nodal marginal zone lymphoma”. Compendium of Cancer Genome Aberrations (CCGA), Cancer Genomics Consortium (CGC), updated {{REVISIONMONTH}}/{{REVISIONDAY}}/{{REVISIONYEAR}}, <nowiki>https://ccga.io/index.php/HAEM5:Paediatric_nodal_marginal_zone_lymphoma</nowiki>. | <nowiki>*</nowiki>''Citation of this Page'': “Paediatric nodal marginal zone lymphoma”. Compendium of Cancer Genome Aberrations (CCGA), Cancer Genomics Consortium (CGC), updated {{REVISIONMONTH}}/{{REVISIONDAY}}/{{REVISIONYEAR}}, <nowiki>https://ccga.io/index.php/HAEM5:Paediatric_nodal_marginal_zone_lymphoma</nowiki>. | ||
[[Category:HAEM5]][[Category:DISEASE]][[Category:Diseases P]] | [[Category:HAEM5]] | ||
[[Category:DISEASE]] | |||
[[Category:Diseases P]] | |||